Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.

Enferm Infecc Microbiol Clin 2017 Oct 6;35(8):493-498. Epub 2016 Apr 6.

Hospital Universitari Germans Trias i Pujol, Badalona; Universitat Autònoma de Barcelona, Spain.

Introduction: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in HIV-mono-infected patients and co-infected with HCV and/or HBV treated with maraviroc.

Methods: Retrospective multicentre cohort study of HIV-infected patients receiving treatment with a maraviroc-containing regimen in 27 hospitals in Spain.

Results: A total of 667 patients were analyzed, of whom 313 were co-infected with HCV (n=282), HBV (n=14), or both (n=17). Maraviroc main indications were salvage therapy (52%) and drug toxicity (20%). Grade 3-4 hypertransaminasaemia (AST/ALT >5 times ULN) per 100 patient-years of maraviroc exposure, was 5.84 (95% CI, 4.04-8.16) and 1.23 (95% CI, 0.56-2.33) in co-infected and HIV-mono-infected patients, respectively (incidence rate ratio, 4.77; 95% CI, 2.35-10.5). However, the degree of aminotransferase abnormalities remained stable throughout the study in both groups, and no significant between-group differences were seen in the cumulative proportion of patients showing an increase in AST/ALT levels greater than 3.5 times baseline levels. No between-group differences were seen in liver fibrosis over time. With a maraviroc median exposure of 20 months (IQR, 12-41), two patients (0.3%) discontinued maraviroc because of grade 4 hepatitis, and other 2 died due to complications associated to end-stage-liver disease.

Conclusions: Maraviroc-containing regimens showed a low incidence of hepatitis in a large Spanish cohort of HIV-infected patients, including more than 300 patients co-infected with HCV and/or HBV. Co-infection did not influence the maximum liver enzyme level or the fibrosis progression throughout the study.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eimc.2016.02.029DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
October 2017
26 Reads

Publication Analysis

Top Keywords

co-infected hcv
12
and/or hbv
12
hcv and/or
12
hepatic safety
12
patients co-infected
12
patients
10
hiv-infected patients
8
fibrosis progression
8
between-group differences
8
safety maraviroc
8
hiv-mono-infected patients
8
maraviroc
7
co-infected
5
degree aminotransferase
4
increase ast/alt
4
ratio 477
4
235-105 degree
4
aminotransferase abnormalities
4
95% 235-105
4
477 95%
4

Similar Publications